TABLE OF CONTENTS
1. EXECUTIVE SUMMARY
2. MARKET INTRODUCTION
2.1. Definition
2.2. Scope of the Study
2.2.1. Research Objective
2.2.2. Assumptions
2.2.3. Limitations
3. RESEARCH METHODOLOGY
3.1. Overview
3.2. Data Mining
3.3. Secondary Research
3.4. Primary Research
3.4.1. Primary Interviews and Information Gathering Process
3.4.2. Breakdown of Primary Respondents
3.5. Forecasting Model
3.6. Market Size Estimation
3.6.1. Bottom-Up Approach
3.6.2. Top-Down Approach
3.7. Data Triangulation
3.8. Validation
4. MARKET DYNAMICS
4.1. Overview
4.2. Drivers
4.3. Restraints
4.4. Opportunities
5. MARKET FACTOR ANALYSIS
5.1. Value Chain Analysis
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining Power of Suppliers
5.2.2. Bargaining Power of Buyers
5.2.3. Threat of New Entrants
5.2.4. Threat of Substitutes
5.2.5. Intensity of Rivalry
5.3. COVID-19 Impact Analysis
5.3.1. Market Impact Analysis
5.3.2. Regional Impact
5.3.3. Opportunity and Threat Analysis
6. GLOBAL CELL THERAPY HUMAN RAW MATERIALS MARKET, BY PRODUCT
6.1. Overview
6.2. Cell Culture Media
6.3. Cell Culture Sera
6.4. Cell Culture Supplements
6.4.1. Proteins
6.4.2. Growth Factors
6.4.3. Nucleotides
6.4.4. Other Supplements
6.5. Reagents & Buffers
6.6. Other Raw Materials
7. GLOBAL CELL THERAPY HUMAN RAW MATERIALS MARKET, BY END-USE
7.1. Overview
7.2. Biopharmaceutical & Pharmaceutical Companies
7.3. CROs & CMOs
7.4. Academic & Research Institutions
8. GLOBAL CELL THERAPY HUMAN RAW MATERIALS MARKET, BY REGION
8.1. Overview
8.1. North America
8.1.1. US
8.1.2. Canada
8.2. Europe
8.2.1. Germany
8.2.2. France
8.2.3. UK
8.2.4. Italy
8.2.5. Spain
8.2.6. Rest of Europe
8.3. Asia-Pacific
8.3.1. China
8.3.2. India
8.3.3. Japan
8.3.4. South Korea
8.3.5. Australia
8.3.6. Rest of Asia-Pacific
8.4. Rest of the World
8.4.1. Middle East
8.4.2. Africa
8.4.3. Latin America
9. COMPETITIVE LANDSCAPE
9.1. Overview
9.2. Competitive Analysis
9.3. Market Share Analysis
9.4. Major Growth Strategy in the Global Cell Therapy Human Raw Materials Market,
9.5. Competitive Benchmarking
9.6. Leading Players in Terms of Number of Developments in the Global Cell Therapy Human Raw Materials Market,
9.7. Key Developments and Growth Strategies
9.7.1. New Product Launch/Service Deployment
9.7.2. Merger & Acquisitions
9.7.3. Joint Ventures
9.8. Major Players Financial Matrix
9.8.1. Sales & Operating Income, 2023
9.8.2. Major Players R&D Expenditure. 2023
10. COMPANY PROFILES
10.1. Thermo Fisher Scientific, Inc
10.1.1. Company Overview
10.1.2. Financial Overview
10.1.3. Products Offered
10.1.4. Key Developments
10.1.5. SWOT Analysis
10.1.6. Key Strategies
10.2. ACROBiosystems
10.2.1. Company Overview
10.2.2. Financial Overview
10.2.3. Products Offered
10.2.4. Key Developments
10.2.5. SWOT Analysis
10.2.6. Key Strategies
10.3. STEMCELL Technologies
10.3.1. Company Overview
10.3.2. Financial Overview
10.3.3. Products Offered
10.3.4. Key Developments
10.3.5. SWOT Analysis
10.3.6. Key Strategies
10.4. Merck KGaA
10.4.1. Company Overview
10.4.2. Financial Overview
10.4.3. Products Offered
10.4.4. Key Developments
10.4.5. SWOT Analysis
10.4.6. Key Strategies
10.5. Actylis
10.5.1. Company Overview
10.5.2. Financial Overview
10.5.3. Products Offered
10.5.4. Key Developments
10.5.5. SWOT Analysis
10.5.6. Key Strategies
10.6. RoosterBio, Inc.
10.6.1. Company Overview
10.6.2. Financial Overview
10.6.3. Products Offered
10.6.4. Key Developments
10.6.5. SWOT Analysis
10.6.6. Key Strategies
10.7. PromoCell GMBH
10.7.1. Company Overview
10.7.2. Financial Overview
10.7.3. Products Offered
10.7.4. Key Developments
10.7.5. SWOT Analysis
10.7.6. Key Strategies
10.8. Grifols, S.A.
10.8.1. Company Overview
10.8.2. Financial Overview
10.8.3. Products Offered
10.8.4. Key Developments
10.8.5. SWOT Analysis
10.8.6. Key Strategies
10.9. Charles River Laboratories
10.9.1. Company Overview
10.9.2. Financial Overview
10.9.3. Products Offered
10.9.4. Key Developments
10.9.5. SWOT Analysis
10.9.6. Key Strategies
10.10. Danaher
10.10.1. Company Overview
10.10.2. Financial Overview
10.10.3. Products Offered
10.10.4. Key Developments
10.10.5. SWOT Analysis
10.10.6. Key Strategies
10.11. Akron Biotech
10.11.1. Company Overview
10.11.2. Financial Overview
10.11.3. Products Offered
10.11.4. Key Developments
10.11.5. SWOT Analysis
10.11.6. Key Strategies
10.12. BioIVT
10.12.1. Company Overview
10.12.2. Financial Overview
10.12.3. Products Offered
10.12.4. Key Developments
10.12.5. SWOT Analysis
10.12.6. Key Strategies
10.13. GeminiBio
10.13.1. Company Overview
10.13.2. Financial Overview
10.13.3. Products Offered
10.13.4. Key Developments
10.13.5. SWOT Analysis
10.13.6. Key Strategies
10.14. AllCells
10.14.1. Company Overview
10.14.2. Financial Overview
10.14.3. Products Offered
10.14.4. Key Developments
10.14.5. SWOT Analysis
10.14.6. Key Strategies
10.15. CGT Global
10.15.1. Company Overview
10.15.2. Financial Overview
10.15.3. Products Offered
10.15.4. Key Developments
10.15.5. SWOT Analysis
10.15.6. Key Strategies
11. APPENDIX
11.1. References
11.2. Related Reports
LIST OF TABLES
TABLE 1 GLOBAL CELL THERAPY HUMAN RAW MATERIALS MARKET, SYNOPSIS, 2019-2032
TABLE 2 GLOBAL CELL THERAPY HUMAN RAW MATERIALS MARKET, ESTIMATES & FORECAST, 2019-2032 (USD BILLION)
TABLE 3 GLOBAL CELL THERAPY HUMAN RAW MATERIALS MARKET, BY PRODUCT, 2019-2032 (USD BILLION)
TABLE 4 GLOBAL CELL THERAPY HUMAN RAW MATERIALS MARKET, BY END-USE, 2019-2032 (USD BILLION)
TABLE 5 NORTH AMERICA: CELL THERAPY HUMAN RAW MATERIALS MARKET, BY PRODUCT, 2019-2032 (USD BILLION)
TABLE 6 NORTH AMERICA: CELL THERAPY HUMAN RAW MATERIALS MARKET, BY END-USE, 2019-2032 (USD BILLION)
TABLE 7 US: CELL THERAPY HUMAN RAW MATERIALS MARKET, BY PRODUCT, 2019-2032 (USD BILLION)
TABLE 8 US: CELL THERAPY HUMAN RAW MATERIALS MARKET, BY END-USE, 2019-2032 (USD BILLION)
TABLE 9 CANADA: CELL THERAPY HUMAN RAW MATERIALS MARKET, BY PRODUCT, 2019-2032 (USD BILLION)
TABLE 10 CANADA: CELL THERAPY HUMAN RAW MATERIALS MARKET, BY END-USE, 2019-2032 (USD BILLION)
TABLE 1 EUROPE: CELL THERAPY HUMAN RAW MATERIALS MARKET, BY PRODUCT, 2019-2032 (USD BILLION)
TABLE 2 EUROPE: CELL THERAPY HUMAN RAW MATERIALS MARKET, BY END-USE, 2019-2032 (USD BILLION)
TABLE 3 GERMANY: CELL THERAPY HUMAN RAW MATERIALS MARKET, BY PRODUCT, 2019-2032 (USD BILLION)
TABLE 4 GERMANY: CELL THERAPY HUMAN RAW MATERIALS MARKET, BY END-USE, 2019-2032 (USD BILLION)
TABLE 5 FRANCE: CELL THERAPY HUMAN RAW MATERIALS MARKET, BY PRODUCT, 2019-2032 (USD BILLION)
TABLE 6 FRANCE: CELL THERAPY HUMAN RAW MATERIALS MARKET, BY END-USE, 2019-2032 (USD BILLION)
TABLE 7 ITALY: CELL THERAPY HUMAN RAW MATERIALS MARKET, BY PRODUCT, 2019-2032 (USD BILLION)
TABLE 8 ITALY: CELL THERAPY HUMAN RAW MATERIALS MARKET, BY END-USE, 2019-2032 (USD BILLION)
TABLE 9 SPAIN: CELL THERAPY HUMAN RAW MATERIALS MARKET, BY PRODUCT, 2019-2032 (USD BILLION)
TABLE 10 SPAIN: CELL THERAPY HUMAN RAW MATERIALS MARKET, BY END-USE, 2019-2032 (USD BILLION)
TABLE 11 UK: CELL THERAPY HUMAN RAW MATERIALS MARKET, BY PRODUCT, 2019-2032 (USD BILLION)
TABLE 12 UK: CELL THERAPY HUMAN RAW MATERIALS MARKET, BY END-USE, 2019-2032 (USD BILLION)
TABLE 13 REST OF EUROPE: CELL THERAPY HUMAN RAW MATERIALS MARKET, BY PRODUCT, 2019-2032 (USD BILLION)
TABLE 14 REST OF EUROPE: CELL THERAPY HUMAN RAW MATERIALS MARKET, BY END-USE, 2019-2032 (USD BILLION)
TABLE 15 ASIA-PACIFIC: CELL THERAPY HUMAN RAW MATERIALS MARKET, BY PRODUCT, 2019-2032 (USD BILLION)
TABLE 16 ASIA-PACIFIC: CELL THERAPY HUMAN RAW MATERIALS MARKET, BY END-USE, 2019-2032 (USD BILLION)
TABLE 17 JAPAN: CELL THERAPY HUMAN RAW MATERIALS MARKET, BY PRODUCT, 2019-2032 (USD BILLION)
TABLE 18 JAPAN: CELL THERAPY HUMAN RAW MATERIALS MARKET, BY END-USE, 2019-2032 (USD BILLION)
TABLE 19 CHINA: CELL THERAPY HUMAN RAW MATERIALS MARKET, BY PRODUCT, 2019-2032 (USD BILLION)
TABLE 20 CHINA: CELL THERAPY HUMAN RAW MATERIALS MARKET, BY END-USE, 2019-2032 (USD BILLION)
TABLE 21 INDIA: CELL THERAPY HUMAN RAW MATERIALS MARKET, BY PRODUCT, 2019-2032 (USD BILLION)
TABLE 22 INDIA: CELL THERAPY HUMAN RAW MATERIALS MARKET, BY END-USE, 2019-2032 (USD BILLION)
TABLE 23 AUSTRALIA: CELL THERAPY HUMAN RAW MATERIALS MARKET, BY PRODUCT, 2019-2032 (USD BILLION)
TABLE 24 AUSTRALIA: CELL THERAPY HUMAN RAW MATERIALS MARKET, BY END-USE, 2019-2032 (USD BILLION)
TABLE 25 SOUTH KOREA: CELL THERAPY HUMAN RAW MATERIALS MARKET, BY PRODUCT, 2019-2032 (USD BILLION)
TABLE 26 SOUTH KOREA: CELL THERAPY HUMAN RAW MATERIALS MARKET, BY END-USE, 2019-2032 (USD BILLION)
TABLE 27 REST OF ASIA-PACIFIC: CELL THERAPY HUMAN RAW MATERIALS MARKET, BY PRODUCT, 2019-2032 (USD BILLION)
TABLE 28 REST OF ASIA-PACIFIC: CELL THERAPY HUMAN RAW MATERIALS MARKET, BY END-USE, 2019-2032 (USD BILLION)
TABLE 29 REST OF THE WORLD: CELL THERAPY HUMAN RAW MATERIALS MARKET, BY PRODUCT, 2019-2032 (USD BILLION)
TABLE 30 REST OF THE WORLD: CELL THERAPY HUMAN RAW MATERIALS MARKET, BY END-USE, 2019-2032 (USD BILLION)
TABLE 31 MIDDLE EAST: CELL THERAPY HUMAN RAW MATERIALS MARKET, BY PRODUCT, 2019-2032 (USD BILLION)
TABLE 32 MIDDLE EAST: CELL THERAPY HUMAN RAW MATERIALS MARKET, BY END-USE, 2019-2032 (USD BILLION)
TABLE 33 AFRICA: CELL THERAPY HUMAN RAW MATERIALS MARKET, BY PRODUCT, 2019-2032 (USD BILLION)
TABLE 34 AFRICA: CELL THERAPY HUMAN RAW MATERIALS MARKET, BY END-USE, 2019-2032 (USD BILLION)
TABLE 35 LATIN AMERICA: CELL THERAPY HUMAN RAW MATERIALS MARKET, BY PRODUCT, 2019-2032 (USD BILLION)
TABLE 36 LATIN AMERICA: CELL THERAPY HUMAN RAW MATERIALS MARKET, BY END-USE, 2019-2032 (USD BILLION)
LIST OF FIGURES
FIGURE 1 RESEARCH PROCESS
FIGURE 2 MARKET STRUCTURE FOR THE GLOBAL CELL THERAPY HUMAN RAW MATERIALS MARKET
FIGURE 3 MARKET DYNAMICS FOR THE GLOBAL CELL THERAPY HUMAN RAW MATERIALS MARKET
FIGURE 4 GLOBAL CELL THERAPY HUMAN RAW MATERIALS MARKET, SHARE (%), BY PRODUCT, 2023
FIGURE 5 GLOBAL CELL THERAPY HUMAN RAW MATERIALS MARKET, SHARE (%), BY END-USE, 2023
FIGURE 6 GLOBAL CELL THERAPY HUMAN RAW MATERIALS MARKET, SHARE (%), BY REGION, 2023
FIGURE 7 NORTH AMERICA: CELL THERAPY HUMAN RAW MATERIALS MARKET, SHARE (%), BY REGION, 2023
FIGURE 8 EUROPE: CELL THERAPY HUMAN RAW MATERIALS MARKET, SHARE (%), BY REGION, 2023
FIGURE 9 ASIA-PACIFIC: CELL THERAPY HUMAN RAW MATERIALS MARKET, SHARE (%), BY REGION, 2023
FIGURE 10 REST OF THE WORLD: CELL THERAPY HUMAN RAW MATERIALS MARKET, SHARE (%), BY REGION, 2023
FIGURE 11 GLOBAL CELL THERAPY HUMAN RAW MATERIALS MARKET: COMPANY SHARE ANALYSIS, 2023 (%)
FIGURE 12 THERMO FISHER SCIENTIFIC, INC: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 13 THERMO FISHER SCIENTIFIC, INC: SWOT ANALYSIS
FIGURE 14 ACROBIOSYSTEMS: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 15 ACROBIOSYSTEMS: SWOT ANALYSIS
FIGURE 16 STEMCELL TECHNOLOGIES: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 17 STEMCELL TECHNOLOGIES: SWOT ANALYSIS
FIGURE 18 MERCK KGAA: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 19 MERCK KGAA: SWOT ANALYSIS
FIGURE 20 ACTYLIS.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 21 ACTYLIS.: SWOT ANALYSIS
FIGURE 22 ROOSTERBIO, INC.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 23 ROOSTERBIO, INC.: SWOT ANALYSIS
FIGURE 24 PROMOCELL GMBH: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 25 PROMOCELL GMBH: SWOT ANALYSIS
FIGURE 26 GRIFOLS, S.A.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 27 GRIFOLS, S.A.: SWOT ANALYSIS
FIGURE 28 CHARLES RIVER LABORATORIES: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 29 CHARLES RIVER LABORATORIES: SWOT ANALYSIS
FIGURE 30 DANAHER: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 31 DANAHER: SWOT ANALYSIS
FIGURE 32 AKRON BIOTECH: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 33 AKRON BIOTECH: SWOT ANALYSIS
FIGURE 34 BIOIVT: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 35 BIOIVT: SWOT ANALYSIS
FIGURE 36 GEMINIBIO: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 37 GEMINIBIO: SWOT ANALYSIS
FIGURE 38 ALLCELLS: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 39 ALLCELLS: SWOT ANALYSIS
FIGURE 40 CGT GLOBAL: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 41 CGT GLOBAL: SWOT ANALYSIS
